⚠ Tool for educational and informational purposes only — not investment advice or a recommendation to buy or sell. Investing carries risk of capital loss. Read the full disclaimer.

HLN — Haleon plc

Last scan (Oct. 2, 2026): price $8.72, RSI 28.36, relative volume 1.32x, MACD ⚪ No, score 47.20.

It's trading below its 200-day average, with an RSI of 28.36 in oversold territory — technically weak, though that can also signal the pessimism is already priced in. Neither the MACD nor a range breakout gives a technical entry signal right now. Relative volume of 1.32x is somewhat above normal. The analysts' average target price implies +36.8% upside — one of the score's strongest signals. Today it holds rank #19 in the Medium group on Smart Scanner's upside + relative volume ranking.

back to scanner

Price chart

Price: $8.73 · RSI (14): 21.24 · Rel. volume: 1.15x · Breakout: No

You can zoom by dragging a rectangle over the chart, or with your mouse wheel. Double-click to reset the view.

What analysts say

HLN

Haleon plc Healthcare · Drug Manufacturers - Specialty & Generic

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture…

Buy score 2.2/5 (1 = strong buy, 5 = sell)
5 analysts
  • Buy 3 (60.0%)
  • Hold 2 (40.0%)
  • Sell 0 (0.0%)

Average target price: $11.93 (+36.9% vs. current price) · range $10.0 – $13.77

Healthy Moderate Attention No data

Market cap $38.35B

Total market value of the company (price × shares outstanding).

P/E (trailing) 18.17
?

P/E (trailing): compares the stock's price with its earnings per share over the last 12 months — how many times that earning is being paid for.

In a reasonable range compared to the market's historical average (~20).

P/E (forward) 14.11
?

P/E (forward): same as P/E, but using analysts' estimated earnings per share for the next year.

Same as P/E, using estimated future earnings.

PEG 2.11
?

PEG: the P/E divided by the expected earnings growth rate — relates how expensive the stock is to how fast it's expected to grow.

Above 2: even accounting for expected growth, the price looks expensive.

Debt/Equity 50.2%
?

Debt/Equity: how much debt the company carries per dollar of shareholder equity — measures how leveraged the balance sheet is.

Moderate leverage, normal in many industries.

Net margin 14.55%
?

Net margin: what percentage of each dollar of revenue ends up as net profit, after all costs.

Healthy margin for most industries.

Dividend 2.27%
?

Dividend: what percentage of the stock's price is paid out in cash to shareholders each year.

Pays out a portion of its earnings as cash to shareholders on a recurring basis.

Beta (risk) 0.24
?

Beta: how volatile the stock is compared to the overall market (S&P 500 = 1.0).

Less volatile than the overall market (S&P 500 = 1.0).

General reference ranges, do not vary by sector. Third-party data; may be incomplete. Not investment advice.

💰 Financial Statements (last 3 quarters)

No public financial statements available for HLN.

💰 Financial Statements (last 3 quarters)

No public financial statements available for HLN.

Advertisement

What this chart shows

Third-party market data, for informational purposes. Not investment advice — read the disclaimer.